메뉴 건너뛰기




Volumn 12, Issue 6, 2010, Pages 437-447

Erratum: Novel approaches to inhibition of gastric acid secretion (Current Gastroenterology Reports DOI: 10.1007/s11894-010-0149-5);Novel approaches to inhibition of gastric acid secretion

Author keywords

Gastric H,K ATPase; Gastroesophageal reflux disease; Proton pump inhibitor; Ulcer

Indexed keywords

8 (2,6 DIMETHYLBENZYLAMINO) N (2 HYDROXYETHYL) 2,3 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 6 CARBOXAMIDE; 8 BENZYLOXY 2 METHYLIMIDAZO[1,2 A]PYRIDINE 3 ACETONITRILE; AGN 201904 Z; ALEVIUM; AMOXICILLIN; ANTIBIOTIC AGENT; BENATOPRAZOLE; CIMETIDINE; CLARITHROMYCIN; DEXLANSOPRAZOLE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; LANSOPRAZOLE; NIZATIDINE; OMEPRAZOLE; PANTOPRAZOLE; PLACEBO; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; SORAPRAZAN; TAK 438; UNCLASSIFIED DRUG;

EID: 78649908709     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-010-0159-3     Document Type: Erratum
Times cited : (71)

References (38)
  • 1
    • 0030962574 scopus 로고    scopus 로고
    • Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: A meta-analysis
    • DOI 10.1053/gast.1997.v112.pm9178669
    • N Chiba CJ De Gara JM Wilkinson RH Hunt 1997 Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis Gastroenterology 112 1798 1810 1:STN:280:DyaK2szit1Sitw%3D%3D 10.1053/gast.1997.v112.pm9178669 9178669 (Pubitemid 27240763)
    • (1997) Gastroenterology , vol.112 , Issue.6 , pp. 1798-1810
    • Chiba, N.1    De Gara, C.J.2    Wilkinson, J.M.3    Hunt, R.H.4
  • 2
    • 0028842263 scopus 로고
    • Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects
    • 1:CAS:528:DyaK2MXltlGrtL0%3D 10.1007/BF02065405 7851185
    • S Teyssen ST Chari J Scheid MV Singer 1995 Effect of repeated boluses of intravenous omeprazole and primed infusions of ranitidine on 24-hour intragastric pH in healthy human subjects Dig Dis Sci 40 247 255 1:CAS:528:DyaK2MXltlGrtL0%3D 10.1007/BF02065405 7851185
    • (1995) Dig Dis Sci , vol.40 , pp. 247-255
    • Teyssen, S.1    Chari, S.T.2    Scheid, J.3    Singer, M.V.4
  • 3
    • 0029093565 scopus 로고
    • Turnover of the gastric H+, K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion
    • 1:CAS:528:DyaK2MXos1aqtb8%3D 10.1016/0016-5085(95)90571-5 7557078
    • K Gedda D Scott M Besancon, et al. 1995 Turnover of the gastric H+, K(+)-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion Gastroenterology 109 1134 1141 1:CAS:528: DyaK2MXos1aqtb8%3D 10.1016/0016-5085(95)90571-5 7557078
    • (1995) Gastroenterology , vol.109 , pp. 1134-1141
    • Gedda, K.1    Scott, D.2    Besancon, M.3
  • 4
    • 22844451154 scopus 로고    scopus 로고
    • Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next?
    • 1:CAS:528:DC%2BD2MXpt1Cjt70%3D 10.1111/j.1365-2036.2005.02531.x 16011666
    • R Fass M Shapiro R Dekel J Sewell 2005 Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 22 79 94 1:CAS:528:DC%2BD2MXpt1Cjt70%3D 10.1111/j.1365-2036.2005. 02531.x 16011666
    • (2005) Aliment Pharmacol Ther , vol.22 , pp. 79-94
    • Fass, R.1    Shapiro, M.2    Dekel, R.3    Sewell, J.4
  • 5
    • 21344468618 scopus 로고    scopus 로고
    • Primary-care physicians' perceptions and practices on the management of GERD: Results of a national survey
    • DOI 10.1111/j.1572-0241.2005.41364.x
    • WD Chey JM Inadomi AM Booher, et al. 2005 Primary-care physicians' perceptions and practices on the management of GERD: results of a national survey Am J Gastroenterol 100 1237 1242 10.1111/j.1572-0241.2005.41364.x 15929751 (Pubitemid 40904343)
    • (2005) American Journal of Gastroenterology , vol.100 , Issue.6 , pp. 1237-1242
    • Chey, W.D.1    Inadomi, J.M.2    Booher, A.M.3    Sharma, V.K.4    Fendrick, A.M.5    Howden, C.W.6
  • 6
    • 28944444479 scopus 로고    scopus 로고
    • Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms
    • 10.1016/S0016-5085(03)81145-9
    • J Pezanoski N Guanaratnam M Cowen 2003 Correct and incorrect dosing of proton pump inhibitors and its impact on GERD symptoms Gastroenterology 124 Suppl 1 A228 10.1016/S0016-5085(03)81145-9
    • (2003) Gastroenterology , vol.124 , Issue.SUPPL. 1 , pp. 228
    • Pezanoski, J.1    Guanaratnam, N.2    Cowen, M.3
  • 7
    • 28944449208 scopus 로고    scopus 로고
    • Review article: The unmet needs in delayed-release proton-pump inhibitor therapy in 2005
    • 1:CAS:528:DC%2BD28Xkt1CmsQ%3D%3D 10.1111/j.1365-2036.2005.02715.x 16303032
    • RH Hunt 2005 Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005 Aliment Pharmacol Ther 22 Suppl 3 10 19 1:CAS:528:DC%2BD28Xkt1CmsQ%3D%3D 10.1111/j.1365-2036.2005.02715.x 16303032
    • (2005) Aliment Pharmacol Ther , vol.22 , Issue.SUPPL. 3 , pp. 10-19
    • Hunt, R.H.1
  • 8
    • 77957892163 scopus 로고    scopus 로고
    • Non-steroidal anti-inflammatory drug related injury of the gastrointestinal tract: Clinical picture pathogenesis and prevention
    • in press
    • Scarpignato C, Hunt RH: Non-steroidal anti-inflammatory drug related injury of the gastrointestinal tract: clinical picture pathogenesis and prevention. Gastroenterol Clin North Am 2010, in press.
    • (2010) Gastroenterol Clin North Am
    • Scarpignato, C.1    Hunt, R.H.2
  • 9
    • 58149310707 scopus 로고    scopus 로고
    • Symptoms in patients on long-term proton pump inhibitors: Prevalence and predictors
    • Patients often suffer ongoing moderate or severe symptoms when on long-term treatment. GERD and uninvestigated dyspepsia were associated with poor long-term symptom control
    • • Raghunath AS, Hungin AP, Mason J, Jackson W: Symptoms in patients on long-term proton pump inhibitors: prevalence and predictors. Aliment Pharmacol Ther 2009, 29:431-439. Patients often suffer ongoing moderate or severe symptoms when on long-term treatment. GERD and uninvestigated dyspepsia were associated with poor long-term symptom control.
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 431-439
    • Raghunath, A.S.1    Hungin, A.P.2    Mason, J.3    Jackson, W.4
  • 10
    • 55649097175 scopus 로고    scopus 로고
    • The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inhibitors (PPIs) in GERD trials: A meta-analysis
    • Abstract S1085
    • Yuan Y, Wang CC, Yuan Y, Hunt RH: The proportion of patients who are free of reflux symptoms during the initial days of treatment with proton pump inhibitors (PPIs) in GERD trials: a meta-analysis. Gastroenterology 2008; 134(4, Suppl 1):A174. Abstract S1085.
    • (2008) Gastroenterology , vol.134 , Issue.4 SUPPL. 1
    • Yuan, Y.1    Wang, C.C.2    Yuan, Y.3    Hunt, R.H.4
  • 11
    • 78649908434 scopus 로고    scopus 로고
    • Hunt RH: Nonhealed rate of moderate-severe (LA Classification Grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): Evidence of an unmet need
    • Y Yuan B Vinh 2009 Hunt RH: Nonhealed rate of moderate-severe (LA Classification Grade C and D) erosive esophagitis after 4-8 weeks proton pump inhibitors (PPIs): evidence of an unmet need Gastroenterology 136 Suppl A440
    • (2009) Gastroenterology , vol.136 , Issue.SUPPL. , pp. 440
    • Yuan, Y.1    Vinh, B.2
  • 12
    • 0033548841 scopus 로고    scopus 로고
    • Importance of pH control in the management of GERD
    • DOI 10.1001/archinte.159.7.649
    • RH Hunt 1999 Importance of pH control in the management of GERD Arch Intern Med 159 649 657 1:STN:280:DyaK1M3jtlWisw%3D%3D 10.1001/archinte.159.7.649 10218743 (Pubitemid 29177653)
    • (1999) Archives of Internal Medicine , vol.159 , Issue.7 , pp. 649-657
    • Hunt, R.H.1
  • 13
    • 68049089445 scopus 로고    scopus 로고
    • Hunt RH: Intragastric pH holding time pH∈<∈3 at steady state in healthy volunteers (HV) after once daily PPIs: A predictor for low erosive esophagitis (EE) healing rates?
    • Y Yuan 2009 Hunt RH: Intragastric pH holding time pH∈<∈3 at steady state in healthy volunteers (HV) after once daily PPIs: a predictor for low erosive esophagitis (EE) healing rates? Gastroenterology 136 Suppl M1990
    • (2009) Gastroenterology , vol.136 , Issue.SUPPL. , pp. 1990
    • Yuan, Y.1
  • 14
    • 68049103749 scopus 로고    scopus 로고
    • Night-time pH holding time: What is hidden by the% of time pH∈≥∈4?
    • CC Wang Y Yuan Y Chen RH Hunt 2008 Night-time pH holding time: what is hidden by the% of time pH∈≥∈4? Am J Gastroenterol 103 Suppl 1 S51
    • (2008) Am J Gastroenterol , vol.103 , Issue.SUPPL. 1 , pp. 51
    • Wang, C.C.1    Yuan, Y.2    Chen, Y.3    Hunt, R.H.4
  • 15
    • 50249186798 scopus 로고    scopus 로고
    • Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy
    • 10.1007/s10620-007-0186-6 18322797
    • G Karamanolis T Vanuytsel D Sifrim, et al. 2008 Yield of 24-hour esophageal pH and bilitec monitoring in patients with persisting symptoms on PPI therapy Dig Dis Sci 53 2387 2393 10.1007/s10620-007-0186-6 18322797
    • (2008) Dig Dis Sci , vol.53 , pp. 2387-2393
    • Karamanolis, G.1    Vanuytsel, T.2    Sifrim, D.3
  • 16
    • 55649107574 scopus 로고    scopus 로고
    • Hunt RH: Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: Evidence of an unmet need?
    • Y Yuan 2008 Hunt RH: Intragastric acid suppressing effect of proton pump inhibitors twice daily at steady state in healthy volunteers: evidence of an unmet need? Am J Gastroenterol 103 Suppl S50
    • (2008) Am J Gastroenterol , vol.103 , Issue.SUPPL. , pp. 50
    • Yuan, Y.1
  • 17
    • 33744985235 scopus 로고    scopus 로고
    • Reflux events and sleep: Are we vulnerable?
    • 10.1007/s11894-006-0076-7 16764786
    • WC Orr 2006 Reflux events and sleep: are we vulnerable? Curr Gastroenterol Rep 8 202 207 10.1007/s11894-006-0076-7 16764786
    • (2006) Curr Gastroenterol Rep , vol.8 , pp. 202-207
    • Orr, W.C.1
  • 18
    • 33750466191 scopus 로고    scopus 로고
    • The patient with refractory gastroesophageal reflux disease
    • DOI 10.1111/j.1442-2050.2006.00619.x
    • JE Richter 2006 The patient with refractory gastroesophageal reflux disease Dis Esophagus 19 443 447 1:STN:280:DC%2BD28njsVWruw%3D%3D 10.1111/j.1442-2050.2006.00619.x 17069586 (Pubitemid 44644679)
    • (2006) Diseases of the Esophagus , vol.19 , Issue.6 , pp. 443-447
    • Richter, J.E.1
  • 20
    • 4344654345 scopus 로고    scopus 로고
    • Intragastric acid suppression and pharmacokinelics of twice-daily esomeprazole: A randomized, three-way crossover study
    • DOI 10.1111/j.1365-2036.2004.02079.x
    • PO Katz DO Castell Y Chen, et al. 2004 Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study Aliment Pharmacol Ther 20 399 406 1:CAS:528:DC%2BD2cXnvVyjtrs%3D 10.1111/j.1365-2036.2004.02079.x 15298633 (Pubitemid 39120250)
    • (2004) Alimentary Pharmacology and Therapeutics , vol.20 , Issue.4 , pp. 399-406
    • Katz, P.O.1    Castell, D.O.2    Chen, Y.3    Andersson, T.4    Sostek, M.B.5
  • 21
    • 56349135772 scopus 로고    scopus 로고
    • Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs)
    • WD Chey R Mody L Chen, et al. 2008 Nighttime symptoms and sleep impairment among patients with gastro-esophageal reflux disease (GERD) receiving prescription (Rx) proton pump inhibitors (PPIs) Gastroenterology 134 4 Suppl 1 A323 A324
    • (2008) Gastroenterology , vol.134 , Issue.4 SUPPL. 1
    • Chey, W.D.1    Mody, R.2    Chen, L.3
  • 22
    • 0038796092 scopus 로고    scopus 로고
    • Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: The results of a Gallup survey conducted on behalf of the American Gastroenterological Association
    • 10.1111/j.1572-0241.2003.07531.x
    • R Shaker DO Castell PS Schoenfeld SJ Spechler 2003 Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association Am J Gastroenterol: 98 1487 1493 10.1111/j.1572-0241.2003.07531.x
    • (2003) Am J Gastroenterol , vol.98 , pp. 1487-1493
    • Shaker, R.1    Castell, D.O.2    Schoenfeld, P.S.3    Spechler, S.J.4
  • 23
    • 68049104246 scopus 로고    scopus 로고
    • Evolving issues in the management of reflux disease?
    • Although GERD is common, management still poses many challenges, which are addressed in this paper together with the unmet needs in reflux disease
    • • Yuan Y, Hunt RH Evolving issues in the management of reflux disease? Curr Opin Gastroenterol 2009, 25:342-351. Although GERD is common, management still poses many challenges, which are addressed in this paper together with the unmet needs in reflux disease.
    • (2009) Curr Opin Gastroenterol , vol.25 , pp. 342-351
    • Yuan, Y.1    Hunt, R.H.2
  • 24
    • 3042544378 scopus 로고    scopus 로고
    • +)-ATPase by proton pump inhibitors
    • DOI 10.1021/ja049607w
    • JM Shin YM Cho G Sachs 2004 Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors J Am Chem Soc 126 7800 7811 1:CAS:528:DC%2BD2cXksFelt7g%3D 10.1021/ja049607w 15212527 (Pubitemid 38812770)
    • (2004) Journal of the American Chemical Society , vol.126 , Issue.25 , pp. 7800-7811
    • Shin, J.M.1    Cho, Y.M.2    Sachs, G.3
  • 25
    • 32144435586 scopus 로고    scopus 로고
    • +-ATPase in vitro and in vivo
    • DOI 10.1016/j.bcp.2005.11.030, PII S0006295205007938
    • JM Shin M Homerin F Domagala H Ficheux G Sachs 2006 Characterization of the inhibitory activity of tenatoprazole on the gastric H+, K∈+∈- ATPase in vitro and in vivo Biochem Pharmacol 71 837 849 1:CAS:528: DC%2BD28XhtlKmtLg%3D 10.1016/j.bcp.2005.11.030 16405921 (Pubitemid 43208840)
    • (2006) Biochemical Pharmacology , vol.71 , Issue.6 , pp. 837-849
    • Shin, J.M.1    Homerin, M.2    Domagala, F.3    Ficheux, H.4    Sachs, G.5
  • 26
    • 7444242617 scopus 로고    scopus 로고
    • +-ATPase in vivo
    • DOI 10.1016/j.bcp.2004.07.035, PII S0006295204005581
    • JM Shin G Sachs 2004 Differences in binding properties of two proton pump inhibitors on the gastric H+, K∈+∈-ATPase in vivo Biochem Pharmacol 68 2117 2127 1:CAS:528:DC%2BD2cXovV2hurk%3D 10.1016/j.bcp.2004.07.035 15498502 (Pubitemid 39446139)
    • (2004) Biochemical Pharmacology , vol.68 , Issue.11 , pp. 2117-2127
    • Shin, J.M.1    Sachs, G.2
  • 29
    • 63849135186 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trials
    • 1:CAS:528:DC%2BD1MXltVWmsbc%3D 10.1185/03007990802693883 19232037
    • M Vakily W Zhang J Wu, et al. 2009 Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials Curr Med Res Opin 25 627 638 1:CAS:528:DC%2BD1MXltVWmsbc%3D 10.1185/03007990802693883 19232037
    • (2009) Curr Med Res Opin , vol.25 , pp. 627-638
    • Vakily, M.1    Zhang, W.2    Wu, J.3
  • 30
    • 61849139946 scopus 로고    scopus 로고
    • Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies
    • This study showed that dexlansoprazole MR is highly effective in healing erosive esophagitis and offers benefits over lansoprazole, particularly in moderate-to-severe disease
    • • Sharma P, Shaheen NJ, Perez MC, et al.: Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation-results from two randomized controlled studies. Aliment Pharmacol Ther 2009, 29:731-741. This study showed that dexlansoprazole MR is highly effective in healing erosive esophagitis and offers benefits over lansoprazole, particularly in moderate-to-severe disease.
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 731-741
    • Sharma, P.1    Shaheen, N.J.2    Perez, M.C.3
  • 31
    • 70349687374 scopus 로고    scopus 로고
    • Clinical trial: Efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis-maintenance of healing and symptom relief
    • 1:CAS:528:DC%2BD1MXhtl2kurrE 10.1111/j.1365-2036.2009.04119.x 19681809
    • CW Howden LM Larsen MC Perez, et al. 2009 Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis- maintenance of healing and symptom relief Aliment Pharmacol Ther 30 895 907 1:CAS:528:DC%2BD1MXhtl2kurrE 10.1111/j.1365-2036.2009.04119.x 19681809
    • (2009) Aliment Pharmacol Ther , vol.30 , pp. 895-907
    • Howden, C.W.1    Larsen, L.M.2    Perez, M.C.3
  • 32
    • 45549091042 scopus 로고    scopus 로고
    • Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z
    • This study showed that a PPI prodrug, AGN201904-Z, provided superior acid control over esoemprazole. Longer duration of the effective plasma concentration of drug was achieved by slow absorption of the prodrug
    • • Hunt RH, Armstrong D, Yaghoobi M, et al.: Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008, 28:187-199. This study showed that a PPI prodrug, AGN201904-Z, provided superior acid control over esoemprazole. Longer duration of the effective plasma concentration of drug was achieved by slow absorption of the prodrug.
    • (2008) Aliment Pharmacol Ther , vol.28 , pp. 187-199
    • Hunt, R.H.1    Armstrong, D.2    Yaghoobi, M.3
  • 33
    • 28144455089 scopus 로고    scopus 로고
    • Tolerability, pharmacokinetics and effects on gastric acid secretion after single oral doses of the potassium-competitive acid blocker AZD0865 in healthy male subjects
    • C Nilsson E Albrektson H Rydholm, et al. 2005 Tolerability, pharmacokinetics and effects on gastric acid secretion after single oral doses of the potassium-competitive acid blocker AZD0865 in healthy male subjects Gastroenterology 128 4 Suppl 2 A528
    • (2005) Gastroenterology , vol.128 , Issue.4 SUPPL. 2 , pp. 528
    • Nilsson, C.1    Albrektson, E.2    Rydholm, H.3
  • 34
    • 37849036310 scopus 로고    scopus 로고
    • A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease
    • This article provides a comparison of a short acting K-competitive inhibitor of the H,K-ATPase with a PPI
    • • Dent J, Kahrilas PJ, Hatlebakk J, et al.: A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008, 103:20-26. This article provides a comparison of a short acting K-competitive inhibitor of the H,K-ATPase with a PPI.
    • (2008) Am J Gastroenterol , vol.103 , pp. 20-26
    • Dent, J.1    Kahrilas, P.J.2    Hatlebakk, J.3
  • 37
    • 70549087723 scopus 로고    scopus 로고
    • inventors; Takeda Pharmaceutical Company, assignee Japanese patent WO 2008/108380 A2. September 12
    • Kajino M, Nishida H, Arikawa Y, Hirase K, Ono K, inventors; Takeda Pharmaceutical Company, assignee. Pyrrole compounds. Japanese patent WO 2008/108380 A2. September 12, 2008.
    • (2008) Pyrrole Compounds
    • Kajino, M.1    Nishida, H.2    Arikawa, Y.3    Hirase, K.4    Ono, K.5
  • 38
    • 77957228369 scopus 로고    scopus 로고
    • 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1 H-pyrrol-3-yl]-N- methylmet hanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases
    • Epub ahead of print
    • Hori Y, Imanishi A, Matsukawa J, et al.: 1-[5-(2-Fluorophenyl)-1- (pyridin-3-ylsulfonyl)-1 H-pyrrol-3-yl]-N-methylmet hanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther 2010 (Epub ahead of print).
    • (2010) J Pharmacol Exp Ther
    • Hori, Y.1    Imanishi, A.2    Matsukawa, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.